CD4 and lung carcinoma: FACS analysis revealed that the percentage of Tregs (CD4+CD25+CD127low) among all CD4+ T cells ranged from 3.4% to 15.6% (mean, 8.29%) in 29 lung cancer patients and 5.2% to 12.5% (mean, 7.34%) in 34 healthy controls.